Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults.
Open Access
- 15 May 1998
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 101 (10), 2165-2173
- https://doi.org/10.1172/jci1111
Abstract
Hepatitis C-associated osteosclerosis (HCAO) is a rare disorder characterized by a marked increase in bone mass during adult life. Despite the rarity of HCAO, understanding the mediator(s) of the skeletal disease is of great interest. The IGFs-I and -II have potent anabolic effects on bone, and alterations in the IGFs and/or IGF-binding proteins (IGFBPs) could be responsible for the increase in bone formation in this disorder. Thus, we assayed sera from seven cases of HCAO for IGF-I, IGF-II, IGF-IIE (an IGF-II precursor), and IGFBPs. The distribution of the serum IGFs and IGFBPs between their ternary ( approximately 150 kD) and binary (approximately 50 kD) complexes was also determined to assess IGF bioavailability. HCAO patients had normal serum levels of IGF-I and -II, but had markedly elevated levels of IGF-IIE. Of the IGFBPs, an increase in IGFBP-2 was unique to these patients and was not found in control hepatitis C or hepatitis B patients. IGF-I and -II in sera from patients with HCAO were carried, as in the case of sera from control subjects, bound to IGFBP-3 in the approximately 150-kD complex, which is retained in the circulation. However, IGF-IIE was predominantly in the approximately 50-kD complex in association with IGFBP-2; this complex can cross the capillary barrier and access target tissues. In vitro, we found that IGF-II enhanced by over threefold IGFBP-2 binding to extracellular matrix produced by human osteoblasts and that in an extracellular matrix-rich environment, the IGF-II/IGFBP-2 complex was as effective as IGF-II alone in stimulating human osteoblast proliferation. Thus, IGFBP-2 may facilitate the targeting of IGFs, and in particular IGF-IIE, to skeletal tissue in HCAO patients, with a subsequent stimulation by IGFs of osteoblast function. Our findings in HCAO suggest a possible means to increase bone mass in patients with osteoporosis.Keywords
This publication has 46 references indexed in Scilit:
- Insulin-Like Growth FactorsNew England Journal of Medicine, 1997
- Autocrine down-regulation of collagenase-3 in rat bone cell cultures by insulin-like growth factors.Endocrinology, 1996
- Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix.Endocrinology, 1996
- Influence of insulin-like growth factor-binding protein-2 on plasma clearance and transfer of insulin-like growth factors-I and -II from plasma into mammary-derived lymph and milk of goatsJournal of Endocrinology, 1996
- Doubling skeletal mass during adult life: The syndrome of diffuse osteosclerosis after intravenous drug abuseJournal of Bone and Mineral Research, 1996
- The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomyJournal of Bone and Mineral Research, 1995
- Development and characterization of a conditionally immortalized human fetal osteoblastic cell lineJournal of Bone and Mineral Research, 1995
- Regulation of insulin-like growth factor binding protein 4 by a specific insulin-like growth factor binding protein 4 proteinase in normal human osteoblast-like cells: Implications in bone cell physiologyJournal of Bone and Mineral Research, 1994
- Variables Controlling the Secretion of Insulin-Like Growth Factor Binding Protein-2 in Normal Human Subjects*Journal of Clinical Endocrinology & Metabolism, 1991
- Synthesis and Secretion of Insulin-like Growth Factor II by a Leiomyosarcoma with Associated HypoglycemiaNew England Journal of Medicine, 1988